Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $750
Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $795, Maintains Neutral Rating
Regeneron Pharma Is Maintained at Overweight by Piper Sandler
Regeneron Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,013
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,059
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,059 From $1,184, Maintains Outperform Rating
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
Regeneron Pharmaceuticals Analyst Ratings
UBS Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Cuts Target Price to $738
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186
Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950
Regeneron Pharma Is Maintained at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $565 to $1,152
Regeneron (REGN) Gets a Buy From Bernstein
Citigroup Cuts Regeneron Pharmaceuticals' Price Target to $795 From $895
Regeneron Pharma Is Maintained at Overweight by Wells Fargo
Regeneron Pharmaceuticals Analyst Ratings